Back to top

Research Daily

Thursday, August 4, 2016

Today's must-read reports are for Shire (SHPG), Colgate-Palmolive Co. (CL) and CME Group Inc. (CME).

Shire shares have moved up following the quarterly report, with the specialty pharmaceutical operator beating top- and bottom-line estimates guiding higher following the Baxalta acquisition. The analyst likes the company’s strong position in the attention deficit hyperactivity disorder (ADHD) market coupled with its recent acquisitions, which is expected to bolster its rare disease portfolio. (You can read the full research report on SHPG here>>)

Zacks Rank # 2 (Buy) rated Colgate Palmolive shares are up more than 12% year-to-date, with the company's improved earnings picture following the quartelry release helping sustain the favorable momentum. The analyst likes the fact that Colgate expects another year of robust organic sales growth on the back of new products across categories and geographical regions, which encouraged it to retain its 2016 outlook. (You can read the full research report on CL here>>)

CME Group is a Zacks Rank # 2 (Buy) rated stock and has gained nearly 14% year-to-date on the back of efforts to expand and cross-sell through strategic alliances, acquisitions, new product initiatives and global presence. In the second quarter, the company witnessed solid revenue growth as well as cost-control induced margin expansion. Notably, CME Group registered a year-over-year increase of 10% in average daily volume for Jul 2016.  (You can read the full research report on CME here>>)

Other notable reports in today's write-up include Aflac (AFL), Fiserv (FISV) and CBS Corporation (CBS).

You can find all of today's stock research reports here>>>.

Want to see all of today's Zacks Strong Buys?
Today's 5 additions are just the appetizer. You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 stocks free of charge. There is no better place to start your own stock search. Plus you can also access the full list of must-avoid Zacks Strong Sells and other private research. See the stocks free >>.

Sheraz Mian

Director of Research

Note: Sheraz Mian regularly provides earnings analysis on and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios.

If you want an email notification each time Sheraz publishes a new article, please click here >>

Featured Reports

New Upgrades

New Downgrades

Hess (HES) Weighed Down by Price Concerns

The covering analyst thinks the weak price environment has reduced Hess' ability to generate cash flow. Also, it continues to be dependent on major asset sales to support its capital expenditures